Ovarian Cancer

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
References & Research
Research Papers
Connections
Featured Videos

1. Overview

Ovarian cancer is a malignancy that begins in or near the ovaries and fallopian tubes — the paired organs and the slender tubes that, together with the peritoneal lining of the abdomen, make up the gynecologic tract most affected by this disease. It is the deadliest of the gynecologic cancers, not because it is the most common (it is not — cancers of the uterus and cervix are diagnosed more often), but because it is so frequently found late. In the United States there are roughly 20,000 new cases and about 13,000 deaths each year. Most women are diagnosed only after the disease has already spread within the abdomen.

If you are reading this because you or someone you love has just been diagnosed, the statistics on this page are honest, and some of them are hard. We have chosen not to soften them, because the most useful thing we can do is tell you the truth and then explain it — what the numbers mean, why screening has been so disappointing, and why, despite all of this, ovarian cancer is one of the cancers where treatment has genuinely improved in the last decade. There is real reason for hope, and there is also a great deal that science still does not know. Both things are true at once.

One of the most important shifts in our understanding — so recent that many people, including some clinicians, have not fully absorbed it — is that the most common and lethal type of "ovarian" cancer often does not start in the ovary at all. It begins in the lining of the fallopian tube and then seeds onto the ovary and the abdominal cavity. That single insight has reshaped how doctors think about prevention, and it is the reason some women are now offered tube-removing surgery during operations they were already having for other reasons.

2. Epidemiology

Ovarian cancer accounts for roughly 2.5% of all cancers in women but a disproportionate share — about 5% — of cancer deaths in women, because of how lethal it is once it spreads. The lifetime risk for an average woman is a little over 1 in 70. Worldwide, GLOBOCAN estimates put ovarian cancer among the top causes of gynecologic cancer death, with more than 300,000 new cases globally each year.

It is overwhelmingly a disease of older women. Most cases are diagnosed after menopause, with the median age around the early 60s. It is uncommon before age 40, though it does occur — and certain inherited types and rarer histologies (such as germ-cell tumors) can appear in younger women and even teenagers.

There are also meaningful patterns in who gets it. Risk is somewhat higher in women of Northern European and Ashkenazi Jewish ancestry — the latter largely because specific BRCA1 and BRCA2 founder mutations are more common in that population. Family history matters a great deal: having one first-degree relative with ovarian cancer roughly triples a woman's own risk, and inherited gene mutations explain a substantial minority of all cases (see Etiology).

3. Pathophysiology

"Ovarian cancer" is not one disease but an umbrella term covering several distinct cancers that happen to share a location. They behave differently, respond to treatment differently, and carry different outlooks. The two broadest families are epithelial tumors (arising from surface-type lining cells) and the much rarer non-epithelial tumors (germ-cell and sex-cord stromal tumors). About 90% of ovarian cancers are epithelial, and within that group the histologic subtypes are:

High-grade serous carcinoma — by far the most common (about 70% of epithelial cases) and the most lethal. This is the type that drives most of the death statistics, and the one now known to usually originate in the fallopian tube.
Endometrioid and clear-cell carcinomas — often linked to endometriosis; clear-cell in particular tends to resist standard chemotherapy.
Low-grade serous carcinoma — slower-growing, often diagnosed younger, driven by different mutations and less responsive to chemo but sometimes responsive to hormone-blocking drugs.
Mucinous carcinoma — uncommon; when truly ovarian it behaves differently again, and pathologists must rule out a spread from the gastrointestinal tract.

The fallopian-tube origin — why it matters. For most of medical history, doctors assumed high-grade serous cancer grew from the surface of the ovary. Then, in the 2000s, pathologists examining tubes removed from BRCA carriers found a tiny precancerous lesion — a serous tubal intraepithelial carcinoma (STIC) — sitting at the far (fimbrial) end of the fallopian tube, where it brushes against the ovary each month. The genetics of these tube lesions matched the genetics of the "ovarian" tumors. The modern view is that many high-grade serous cancers start in the fallopian tube and only later land on the ovary, which is simply the closest, most welcoming soil. This is not a technicality. It changed prevention: if you remove the fallopian tubes, you may remove the launch site of the most dangerous form of the disease. That logic underlies opportunistic salpingectomy — removing the tubes while leaving the ovaries — now offered to many women during other pelvic operations such as hysterectomy or permanent contraception (see Prevention).

Once high-grade serous cancer is established, it spreads in a characteristic way: cells shed off the tumor and float in the natural fluid that circulates through the abdomen, then implant on the peritoneum (the abdominal lining), the omentum (a fatty apron over the bowel), the surface of the bowel, and the diaphragm. This is why so many women are diagnosed at an advanced "stage III" even when they feel only vaguely unwell — the disease has quietly spread along surfaces rather than forming one large, obvious mass.

4. Etiology and Risk Factors

The single biggest lesson of the last 30 years is that inherited gene mutations cause a large share of ovarian cancer — and that knowing about them changes both prevention and treatment.

BRCA1 and BRCA2. Mutations in these two genes account for roughly 15-20% of all ovarian cancer cases. A woman carrying a BRCA1 mutation has a lifetime ovarian cancer risk on the order of 40-45%; with BRCA2 the figure is lower, around 15-20% — still many times the general-population risk of about 1.5%. These genes normally help cells repair broken DNA; when they fail, damage accumulates and cancer can follow. Crucially, this same repair defect is also the chink in the tumor's armor that PARP inhibitor drugs exploit (see Treatment).

Everyone diagnosed with ovarian cancer should be offered genetic testing — this is now a firm guideline, not an optional extra. The reason is twofold: a positive result opens the door to PARP-inhibitor treatment that can dramatically extend remission, and it gives blood relatives the chance to learn their own risk and act on it before cancer ever appears.

Lynch syndrome (hereditary nonpolyposis colorectal cancer) is the other major inherited cause. The mismatch-repair gene mutations behind Lynch raise the risk of ovarian, endometrial, and colorectal cancers, and account for a smaller but real fraction of cases — often the endometrioid and clear-cell types.

Beyond genetics, established risk factors include:

Age — risk climbs steadily after menopause.
Never having been pregnant, and early first period / late menopause — broadly, more lifetime ovulation appears to mean more risk, which is part of why pregnancy and the pill are protective.
Endometriosis — modestly raises the risk of clear-cell and endometrioid subtypes specifically.
Family history of ovarian, breast, or colorectal cancer.
Hormone therapy after menopause — estrogen-only therapy used long-term carries a small increase in risk.

It is worth saying plainly what is not a clearly established cause. The old worry about talc powder remains scientifically unsettled and any effect, if real, is small. Most women who develop ovarian cancer have no identifiable risk factor at all — which is exactly why "I did everything right" and "this is not your fault" are both true.

5. Clinical Presentation

Ovarian cancer earned a cruel nickname — "the silent killer" — but that label is not quite accurate, and the correction matters. Research led by Dr. Barbara Goff and colleagues showed that most women do have symptoms; the trouble is that the symptoms are vague, common, and easy to attribute to something else. A better description is the "whispering" cancer. It speaks — quietly — and the skill is in learning to listen.

The cluster of symptoms most associated with ovarian cancer, identified in the Goff symptom index, is:

Persistent bloating or a feeling of abdominal fullness or increased size.
Early satiety — feeling full quickly, or difficulty eating.
Pelvic or abdominal pain.
Urinary urgency or frequency — needing to go more often or more suddenly.

Here is the part to remember, because it can genuinely save a life. These symptoms are everywhere in everyday life — almost every adult has had a bloated, achy, need-the-bathroom day. What separates ordinary discomfort from a warning sign is the pattern. The combination that should prompt evaluation is symptoms that are new (not your normal), frequent (more than about 12 days a month), and persistent for two weeks or more. If that describes you, the right move is not to wait it out — it is to see a doctor and specifically mention these symptoms together. Ask directly: "could this be ovarian?" You are not being dramatic. You are being exactly as careful as you should be.

Other, later signs can include unexplained weight loss, fatigue, back pain, constipation, and changes in menstruation. In advanced disease, fluid can build up in the abdomen (ascites), causing the belly to swell noticeably — sometimes the first thing that finally sends a woman to her doctor.

6. Diagnosis

When ovarian cancer is suspected, the work-up is usually quick and follows a logical chain.

Pelvic examination may reveal a mass, though small or early tumors are easily missed by hand. Transvaginal ultrasound is the first imaging test — it looks at the ovaries directly and can flag features that raise concern: solid areas, thick walls, internal projections, and abnormal blood flow. CT scans of the abdomen and pelvis (and sometimes chest) then map how far disease may have spread, which guides the surgical plan.

The CA-125 blood test — and its real limits. CA-125 is a protein often elevated in ovarian cancer, and it is genuinely useful in the right context. But it is not a reliable screening test, and understanding why protects you from both false alarm and false reassurance. CA-125 can be elevated for many harmless or unrelated reasons — endometriosis, uterine fibroids, pelvic inflammation, liver disease, even normal menstruation and early pregnancy. And it can be normal in some women who do have cancer, especially with early-stage or non-serous types. So a high CA-125 does not mean cancer, and a normal one does not rule it out. Where CA-125 truly shines is after diagnosis: tracking the number over time is an excellent way to monitor whether treatment is working and whether disease is coming back. A related marker, HE4, is sometimes combined with CA-125 to refine risk estimates.

The diagnosis is confirmed surgically. Unlike many cancers, ovarian cancer is generally not biopsied through the skin first (for fear of spreading tumor cells along the needle track). Instead, the same operation that removes the cancer also stages it and provides tissue for the pathologist. Surgical staging determines how far the disease has spread, from stage I (confined to the ovaries or tubes) to stage IV (spread to distant organs). The majority of high-grade serous cases are stage III at diagnosis — already seeded throughout the abdomen — which is the central, painful fact behind the survival numbers.

7. Treatment

Treatment for ovarian cancer rests on two pillars — surgery and chemotherapy — with a third, maintenance therapy (especially PARP inhibitors), added over the last decade that has changed outcomes for the better.

Surgery — and why the surgeon matters. The central goal of surgery is cytoreduction, or "debulking" — removing as much visible tumor as humanly possible. This typically means removing the ovaries, tubes, uterus, the omentum, and any peritoneal deposits. The phrase to know is "no residual disease" (sometimes "R0"): outcomes are dramatically better when the surgeon is able to leave behind no visible tumor at all. And here is something every patient deserves to hear: who does the surgery matters enormously. Operations performed by a gynecologic oncologist at a high-volume center are consistently associated with more complete debulking and longer survival than the same operation done by a general surgeon or general gynecologist. If at all possible, ask to be referred to a gynecologic oncologist before surgery — not after. Sometimes chemotherapy is given first to shrink the tumor (neoadjuvant chemotherapy) so that surgery can be more complete; this is a reasonable, evidence-based path, not a sign that anyone has given up.

Chemotherapy. The backbone is a platinum drug (carboplatin) combined with a taxane (paclitaxel). This pairing has been the standard for decades because high-grade serous cancer is, at first, usually very sensitive to platinum. Chemo is typically given after surgery (and sometimes before). Most women respond well to this first round — which is part of why a recurrence later can feel so blindsiding.

PARP inhibitors — the maintenance revolution. This is the genuinely good news of the past decade. PARP inhibitors (olaparib, niraparib, rucaparib) are pills taken after chemotherapy to keep the cancer in remission longer. They work by exploiting the very DNA-repair weakness that BRCA mutations create — a strategy called "synthetic lethality." In the SOLO-1 trial, women with newly diagnosed BRCA-mutated advanced ovarian cancer who took maintenance olaparib had a profound, durable improvement in staying cancer-free, with a large fraction in long-term remission years later. The PRIMA trial extended a benefit to a broader group with niraparib, and the PAOLA-1 trial showed olaparib plus bevacizumab helped certain women further. These drugs do not cure everyone, and they have side effects (fatigue, nausea, low blood counts), but they represent the first major leap forward in ovarian cancer treatment in a generation.

Bevacizumab (Avastin), an antibody that starves tumors of their blood supply, is added in some situations and was studied in the GOG-218 trial. Hormone-blocking therapy can help the slow-growing low-grade serous type, and clinical trials of immunotherapy and antibody-drug conjugates continue.

Recurrence — explained kindly. Many women with advanced ovarian cancer will, sadly, see the disease return. When it does, doctors classify it by how the cancer responds to platinum, and this is worth understanding because it shapes the next plan. If the cancer comes back more than six months after platinum chemo finished, it is called platinum-sensitive — and the good news is that platinum often works again, sometimes for years of repeated remissions. If it returns sooner than six months, it is platinum-resistant, and other drugs are used instead. This is not a verdict on you or anything you did. It is simply biology, and even platinum-resistant disease has growing treatment options. For many women today, ovarian cancer has become a chronic illness managed over years rather than a single battle, with each remission bought by a new round of treatment.

8. Complications

Complications arise both from the disease and from its treatment. From the cancer itself, the most common are ascites (fluid buildup in the abdomen, causing swelling, discomfort, and breathlessness when severe) and bowel obstruction — when tumor on the surface of the intestines blocks the passage of food. Bowel obstruction is one of the most distressing complications of advanced ovarian cancer and a frequent reason for hospital admission; it can sometimes be relieved surgically and otherwise managed with medication and rest of the bowel.

From treatment, surgery carries the usual risks of major abdominal operations, and the removal of both ovaries before natural menopause causes immediate surgical menopause — hot flashes, bone-density loss, and other changes that may need their own management. Chemotherapy brings fatigue, nausea, hair loss, infection risk from low white-cell counts, and nerve damage (neuropathy) from taxanes. PARP inhibitors can lower blood counts and, rarely, raise the risk of secondary blood cancers with long use. Good supportive care — for nausea, pain, nutrition, and the emotional weight of all of it — is not a luxury; it is part of proper treatment.

9. Prognosis

This is the hardest section, and we will be straight with you. Overall, about half of women diagnosed with ovarian cancer are alive five years later (the figure hovers around 50%, somewhat higher in recent years). That number is sobering, and it reflects how late most cases are found.

But the average hides something important — stage at diagnosis changes everything. When ovarian cancer is caught early, while still confined to the ovary or tube (stage I, "localized"), the five-year survival is roughly 90-93%. The tragedy, and the reason the overall number is so much worse, is that only about 1 in 5 cases is found that early. Most are discovered at stage III or IV, where five-year survival falls to around 30% or lower. The gap between those two worlds — 90%-plus if caught early, far less if caught late — is precisely why the symptom awareness in Section 5 is not a small matter.

Other factors shape the individual outlook: tumor type and grade (low-grade serous behaves more gently than high-grade), whether the surgeon achieved no residual disease, and BRCA status — women with BRCA mutations, somewhat counterintuitively, often respond especially well to platinum chemo and PARP inhibitors and tend to do better than average. Statistics describe groups, not people. They cannot tell you what will happen to one particular woman, and individuals routinely live well beyond what the averages predicted.

10. Prevention

There is no vaccine and no simple screening test, but several real, evidence-based things lower risk.

Oral contraceptives. The birth-control pill is one of the most powerful protective factors known for ovarian cancer. A large collaborative reanalysis pooling 45 studies found that the pill substantially reduces ovarian cancer risk, and the protection grows with longer use and persists for decades after stopping. With five or more years of use, the risk reduction is commonly cited in the range of 30-50%. We state this honestly because it is one of the best-established findings in the field. The pill is not right for everyone and carries its own trade-offs, but for a woman at elevated risk it is worth an informed conversation with her doctor.

Other factors that lower risk, broadly by reducing lifetime ovulation or removing tissue: pregnancy, breastfeeding, and tubal ligation ("getting your tubes tied"), which on its own lowers risk and, as discussed below, can be extended into full tube removal.

Risk-reducing surgery for high-risk women. For women with a confirmed BRCA or Lynch mutation, the most effective protection is risk-reducing salpingo-oophorectomy — removing the tubes and ovaries, typically after childbearing is complete and around the recommended ages for each gene. This dramatically lowers ovarian cancer risk (and, for BRCA carriers, breast cancer risk as well). It brings on surgical menopause, so it is a serious, deeply personal decision made with a genetics counselor and gynecologic oncologist.

Opportunistic salpingectomy. Flowing directly from the fallopian-tube origin discovery, surgeons now offer to remove the fallopian tubes (while leaving the ovaries in place) during operations a woman is already having for other reasons — a hysterectomy for fibroids, or permanent contraception. Removing the tubes takes away the most likely launch site of high-grade serous cancer without causing menopause, since the ovaries stay. It is a low-cost, low-risk addition that may prevent some of the deadliest cancers, and it is increasingly recommended for average-risk women undergoing those surgeries.

Why there is no general screening test — the honest answer. This question deserves a direct and somewhat unsatisfying answer, because the temptation to imagine a yearly blood test or ultrasound is so natural. Researchers tried exactly that. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) enrolled more than 200,000 women and followed them for years, testing screening with CA-125 (interpreted over time) and ultrasound against no screening. Despite a smart, sophisticated design, screening did not save lives — it did not meaningfully reduce deaths from ovarian cancer. This is the truthful result, and major guideline bodies therefore recommend against routine screening of average-risk women, because screening that does not reduce death but does produce false alarms and unnecessary surgeries can do more harm than good. It is a genuinely disappointing answer. But "we tested it carefully and it did not work" is more respectful of women than pretending otherwise — and it is exactly why symptom awareness and genetic testing of families carry so much weight right now.

11. Recent Research and Advances

Ovarian cancer research is one of the more hopeful corners of oncology at the moment, with several lines of work moving quickly.

PARP inhibitors keep expanding. Beyond the first-line maintenance success of SOLO-1, PRIMA, and PAOLA-1, trials such as NOVA (niraparib) and ARIEL3 (rucaparib) established PARP-inhibitor maintenance after recurrence in platinum-sensitive disease, and SOLO2 confirmed durable benefit in BRCA-mutated relapse. Researchers are now working out how to help the larger group of women whose tumors lack a BRCA-type repair defect, and how to overcome resistance when it develops.

Homologous recombination deficiency (HRD) testing is refining who benefits. Some tumors without a BRCA mutation still carry the same broad DNA-repair weakness ("HRD-positive") and respond to PARP inhibitors; molecular tests now help identify them, pushing treatment toward a more personalized model.

Folate-receptor-targeted therapy arrived recently: mirvetuximab soravtansine, an antibody-drug conjugate that delivers chemotherapy directly to tumor cells displaying a particular receptor, became an option for certain platinum-resistant cancers — a meaningful step in a setting that had seen little progress.

Earlier detection remains the holy grail. Because UKCTOCS showed conventional screening does not save lives, attention has turned to next-generation approaches — circulating tumor DNA ("liquid biopsy"), multi-marker blood panels, and proteomic signatures — aimed at catching the disease at the curable stage I, when survival exceeds 90%. None is ready for routine use yet, but this is where a true breakthrough would matter most.

12. References & Research

Historical Background

For most of the twentieth century, ovarian cancer was treated chiefly with radical surgery, and the outlook was grim. The arrival of cisplatin in the 1970s — a platinum compound whose anticancer power was discovered almost by accident — was the first true turning point, finally giving oncologists a drug to which ovarian cancer often responded. Paclitaxel, originally isolated from the bark of the Pacific yew tree, joined the regimen in the 1990s and, paired with carboplatin, became the standard backbone still used today. The 1994 cloning of the BRCA1 gene (and soon after, BRCA2) revealed why ovarian and breast cancer cluster in families and laid the genetic groundwork for everything that followed. The 2000s brought a conceptual revolution — the recognition that many "ovarian" high-grade serous cancers actually begin in the fallopian tube — reshaping prevention. And from 2014 onward, the approval of PARP inhibitors opened the modern era of maintenance therapy, the first major improvement in survival in a generation.

Key Research Papers

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263.
Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index. Cancer. 2007;109(2):221-227.
Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. The Journal of Pathology. 2007;211(1):26-35.
Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71.
Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet. 2016;387(10022):945-956.
Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies. The Lancet. 2008;371(9609):303-314.
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine. 2006;354(1):34-43.
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine. 2011;365(26):2473-2483.
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis by BRCA status. The Lancet Oncology. 2014;15(8):852-861.
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine. 2016;375(22):2154-2164.
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer (SOLO-1). New England Journal of Medicine. 2018;379(26):2495-2505.
González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer (PRIMA). New England Journal of Medicine. 2019;381(25):2391-2402.
Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer (PAOLA-1). New England Journal of Medicine. 2019;381(25):2416-2428.
Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. New England Journal of Medicine. 2019;380(13):1256-1266.

Research Papers

The links below run live searches on PubMed, the U.S. National Library of Medicine's database of biomedical literature. Use them to find the most current peer-reviewed research on each aspect of ovarian cancer — the results update as new studies are published.

Connections

Back to Table of Contents